Dianthus | Affinity Screening
-
2:55WatchGet fast, non-stop, highly sensitive hit screening with Dianthus.
Dianthus removes the complexity of binding interaction measurements for drug discovery screening. Find hits for any target type in any buffer or bioliquid, measure the tightest interactions down to pi
-
ReadTargeted protein degradation promises to lead the way to effective drugs for challenging targets
-
Read
Because you demand fast, non-stop, highly sensitive hit screening.
-
Ready to tackle your challenging affinity screening?
Learn more
Discover tools you can use -
ReadHigh-throughput determination of protein affinities using unmodified peptide libraries in nanomolar scale
-
35:47WatchImprove your protein degrader design with new ways to discover E3 ligase ligands
Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
-
ReadFast Mek1 hit identification with TRIC technology correlates well with other biophysical methods
-
56:52WatchAdventures in drug discovery - The quest for your best small molecule
Are you working in the field of small molecule drug discovery? Join this webinar to explore the drug discovery workflow and discover tools that can help in your quest for the most promising lead com
-
59:35WatchUnderstanding the nuances of targeted protein degradation
Bifunctional degrader molecules (also known as PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases. The formation of a ternary complex between PROTAC, ligase, and the protein of inte
-
Read
Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus
-
Read
Are you building an effective protein degrader?
-
ReadProtein degraders show promising results in drug development pipelines. See what progress candidates have made.
There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...
-
ReadIs your screening campaign stuck? 3 signs that it’s time to look for an alternative biophysical technology
Most labs dedicated to drug discovery — in big pharma, biopharma, or CROs — make it a priority to have an adequate lineup of instruments for their screening campaigns. They decide on what...
-
Read
Going small to win big: Fragment-based screening in drug discovery
-
ReadFollow these 7 tips when pipetting small volumes to get consistent assay results
If you’ve ever had to pipette really small volumes, such as what is required in 384-well plates, you’re definitely familiar with the frustrations that come along with it. The concentration alone...
-
Read4 ways to help you overcome the limitations of current methods in neurodegenerative disease research
-
Read6 protein degradation conferences in 2021 you can’t afford to miss
Conferences in 2021 will gather scientists and experts eager to discuss new discoveries in the emerging field of targeted protein degradation (TPD). Many transcription factors, scaffold proteins,...
-
Read3 case studies on how to characterize challenging drug discovery targets — membrane proteins, peptide libraries, and PROTACs
A caveat to a successful pharmaceutical industry in which many effective drugs have already been discovered is the notion that the high hanging fruits left unpicked come in the form of challenging...
-
ReadThe NanoTemper Story – Chapter 5: The Dianthus
Almost as soon as the Monolith launched, the handful of people that made up NanoTemper in those early days huddled around, brainstorming how to translate the technology into a well-based assay....
-
17:10WatchTackle the high-hanging fruits in challenging drug discovery pipelines
There are a number of interesting drug targets that have a reputation of being especially difficult to study in biochemical or biophysical assays. Join us to learn how Dianthus can help you address t
-
Read
Fast molecular interaction screening of epigenetic gene regulator G9a with fragments from a large chemical space
-
Loading more...
